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Abstract
Background: The use of economic evaluations in healthcare decision-making can potentially help decision-makers
in allocating scarce resources as efficiently as possible. Over a decade ago, the use of such studies was found to be
limited in Dutch healthcare decision-making, but their current use is unknown. Therefore, this study aimed to
provide insight into the current and potential use of economic evaluations in Dutch healthcare decision-making
and to identify barriers and facilitators to the use of such studies.
Methods: Interviews containing semi-structured and structured questions were conducted among Dutch healthcare
decision-makers. Participants were purposefully selected and special efforts were made to include decision-makers
working at the macro- (national), meso- (local/regional), and micro-level (patient setting). During the interviews, a topic
list was used that was based on the research questions and a literature search, and was developed in consultation with
the Dutch National Healthcare Institute. Responses to the semi-structured questions were analyzed using a
constant comparative approach. As for the structured questions, participants’ definitions of various economic
evaluation concepts were scored as either being “correct” or “incorrect” by two researchers, and summary statistics
were prepared.
Results: Sixteen healthcare decision-makers were interviewed and two health economists. Decision-makers’ knowledge
of economic evaluations was only modest, and their current use appeared to be limited. Nonetheless, decision-makers
recognized the importance of economic evaluations and saw several opportunities for extending their use at the
macro- and meso-level, but not at the micro-level. The disparity between the limited use and recognition of the
importance of economic evaluations is likely due to the many barriers decision-makers experience preventing
their use (e.g. lack of resources, lack of formal willingness-to-pay threshold). Possible facilitators for extending the use of
economic evaluations include, amongst others, educating decision-makers and the general population about economic
evaluations and presenting economic evaluation results in a clearer and more understandable way.
Conclusions: This study demonstrated that the current use and impact of economic evaluations in Dutch healthcare
decision-making is limited at best. Therefore, strategies are needed to overcome the barriers that currently prevent
economic evaluations from being used extensively.
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Background
As in other developed countries, a large proportion of
the Dutch Gross Domestic Product is spent on health-
care, and this proportion has grown during the last
decade, from 9% in 2004 to 11% in 2014 [1]. It has been
suggested that such increases can be explained by factors
outside the healthcare sector (e.g. ageing population,
increased prevalence of chronic diseases), the absence of
a competitive market within healthcare systems, the
absence of strong cost-containment measures, and
technological innovation [2, 3]. Of them, technological
innovation is often cited as the main driver of the
long-term growth in healthcare costs [3–5]. It must be
noted that high and rising healthcare costs are not
necessarily associated with negative connotations. Cost
increases may be synonymous with improved health out-
comes, increases in job opportunities in the sector, and
improved quality of services delivered [2, 6]. However,
since the rate of increase in healthcare costs currently
exceeds economic growth, its continued growth at current
rates is not sustainable and public spending on healthcare
is crowding out public spending on other services. As a
consequence, there is a strong (political) call for health-
care cost-containment and healthcare decision-makers are
increasingly being confronted with choices about which
treatments to reimburse and which to not reimburse [7].
Economic evaluations provide an indication of the
relative efficiency of treatments by comparing the costs
and consequences of alternative programs or interventions
[8]. Such studies can help healthcare decision-makers to
determine how best to allocate scarce resources at the
macro-, meso-, and micro-level. At the macro-level, the
Dutch Ministry of Health, Welfare, and Sports has to de-
cide upon the content of the basic health insurance pack-
age (i.e. a compulsory insurance for all Dutch citizens). In
making such decisions they are advised by the Dutch
National Healthcare Institute, an independent governing
body that, amongst others, provides evidence-based guid-
ance and advice on the in- or exclusion of healthcare
services in the basic health insurance package as well as
the conduct of economic evaluations [9, 10]. The majority
of the content of the basic health insurance package, how-
ever, is somewhat openly formulated [10]. This means that
‘insured care’ is defined in terms of functions of care
rather than in specific healthcare services [10]. As a conse-
quence, the responsibility for ‘appropriate use’ of insured
care, and thus the allocation of the healthcare budget, is
partly transferred to institutions and healthcare providers
working at the regional or local level (i.e. meso-level) and
in the individual patient setting (i.e. micro-level) [11].
Various studies indicated that healthcare decision-makers
in many Western countries have a positive attitude towards
the use of economic evaluations for resource allocation de-
cision-making, but that their use and knowledge of
economic evaluations is limited [12–17]. This discrep-
ancy is likely due to the various barriers that decision-
makers experience preventing their use in day-to-day
decision-making, such as a lack of resources, political
opposition, and a lack of relevant studies [12–17]. The
only Dutch study to explore the use of economic evalu-
ations in healthcare decision-making was performed
more than a decade ago (i.e. 1998–1999) [17]. However,
in an effort to improve the quality and efficiency of
care, the Dutch government introduced a new Health
Insurance Act in 2006, changing the healthcare system
from a partly public and partly private, predominantly
government-run system, into a universal insurance market
that aims to be competitive [10]. Amongst others, the new
act mandates all Dutch citizens to purchase the basic health
insurance package, all insurance companies have to offer
the basic health insurance package, and competing health
insurance companies are obliged to accept all applicants
during an annual enrollment period [10]. As one of the
main aims of the Dutch healthcare reform was to improve
the efficiency of healthcare [10, 18], it is conceivable that
the decision-makers’ knowledge and use of economic eval-
uations have increased since then. Whether this is indeed
the case, however, is currently unknown. Therefore, this
study aimed to gain insight into the current and potential
use of economic evaluations in Dutch healthcare decision-
making and to identify barriers and facilitators to the use of
such studies.
Methods
Interviews containing both semi-structured and struc-
tured questions were conducted among Dutch healthcare
decision-makers to explore their economic evaluation
knowledge and skill set, the current and potential use
of economic evaluations in the healthcare decision-
making context, as well as barriers and facilitators to
the use of such studies. For the purpose of this study,
“healthcare decision-maker” was defined as a profes-
sional who has influence on the allocation of the Dutch
healthcare budget at the macro-, meso-, and/or micro-
level. A predominantly qualitative approach was used
in order to explore the questions under study in greater
detail and to obtain in-depth information on the views
and opinions of the participants [19].
Study population
Participants were purposefully selected using a combination
of critical case and maximum variation sampling, in which
a small, but heterogeneous, sample of information-rich
cases was selected [20, 21]. Special efforts were made to in-
clude decision-makers working at the macro-, meso-, and
micro-level, and in different regions of the Netherlands.
Additionally, two health economists with a deep under-
standing of the Dutch healthcare system were included.
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The Dutch National Healthcare Institute assisted in identi-
fying participants for this study. Participants were also
selected by means of snowballing, i.e. they were referred by
other participants on the basis that they were expected to
be able to provide relevant information [22]. Potential par-
ticipants were contacted via email.
At the start of the interviews, all participants were
informed about the study purpose, were reassured of
confidentiality, and provided verbal informed consent.
The present study was conducted in accordance with
the Declaration of Helsinki. Under Dutch law, ethical
approval was not necessary for this study, since it is not
required for studies that do not infringe the participants’
physical and/or psychological integrity (according to the
Dutch Medical Research Involving Human Subjects Act).
Interviews
Interviews were conducted in Dutch and were carried
out by one researcher (KR) between April and June 2014
at a time and location convenient to the participants.
Participants were informed that they did not have to
prepare for the interviews and were assured that there
were no right or wrong answers. All interviews started
with several short questions about the participants’
demographic and employment characteristics. Subse-
quently, semi-structured questions were asked about
their current and potential use of economic evaluations
for decision-making, as well as barriers and facilitators
to their use. The topic list for the interviews was devel-
oped based on the research questions and a literature
search in PubMed, the Cochrane-library, and Google
Scholar. The literature search was aimed at getting a
general overview of previous studies evaluating the use
of economic evaluations in healthcare decision-making.
The search was conducted by KR, with the help of an
information specialist of the VU University Medical
Centre. Search terms included: “economic evaluation”,
“cost-effectiveness”, “cost-benefit analysis”, “decision-
making”, “healthcare rationing”, “treatment decision”,
“attitude”, “health personnel attitude”, “knowledge”, and
“economic evaluation skills”. For completeness, refer-
ence lists of included studies were screened. Out of 44
publications, 15 articles were selected and studied in-
depth by KR to formulate (sub-) topics. The topic list
was further refined in consultation with two employees
of the Dutch National Healthcare Institute. The final
topic list can be found in Additional file 1.
During the interviews, the topic list was used as a
guide, but participants were allowed to discuss other
topics that they considered to be important as well.
Throughout the interviews, participants were asked to
clarify their answers by providing daily decision-making
examples. To investigate the decision-makers’ knowledge
of economic evaluations (excluding health economists),
interviews ended with a number of structured questions.
First, participants were asked what they associated with
the term ‘economic evaluation’ and whether they had
previously received training in economic evaluation-related
topics. Subsequently, they were asked whether they were
familiar with and could define various economic evaluation
designs, including cost-effectiveness analysis (CEA), cost-
benefit analysis (CBA), and cost-utility analysis (CUA). Dur-
ing the interviews, field notes were taken and interviews
were audio-taped and transcribed verbatim directly after
the interview. As no additional information emerged
from the data after 18 interviews (i.e. data saturation was
reached), the data collection process was terminated.
Data analysis
Using Nvivo 10, data derived from the semi-structured
questions were analysed using a constant comparative
approach. That is, analytic categories were inductively
established by constantly comparing and checking items
with the rest of the data [23]. By starting with open coding,
descriptive themes and subthemes were generated by KR.
That is, transcripts were read line by line and relevant pas-
sages were selected and coded. Throughout this process,
efforts were made to detect further examples of previously
identified (sub-) themes and, if applicable, to identify new
ones. The final codes were developed through discussion
between two researchers (KR and JvD). During these
discussions, similar codes were grouped into analytical
categories and the different properties of these categor-
ies were explored (i.e. the characteristics of these cat-
egories) as well as the relationships between them (i.e.
relating categories to each other) [24, 25]. For the pur-
pose of this article, quotes were translated from Dutch
to English by the research team and were carefully edi-
ted slightly to make them more readable without losing
their meaning.
Data derived from the structured-questions were ana-
lyzed using descriptive statistics. For this purpose, KR
and JvD independently scored the participants’ definitions
of CEA, CUA, and CBA as ‘correct’ or ‘incorrect’. Defini-
tions were scored as ‘correct’ if they included some com-
bination of the following information: CEA, a comparison
of costs and effects, in which effects are expressed in terms
of health effects (other than those expressed in terms of a
quality of life measure or a monetary value); CUA, a com-
parison of costs and effects, where effects are expressed in
QALYs (quality adjusted life years) or an appropriate vari-
ant taking quality of life into account; CBA, a comparison
of costs and benefits, where the benefits get a monetary
value [25]. In all other cases, they were scored as ‘incor-
rect’. After both researchers independently scored the
definitions, scores were compared and disagreements
(n = 6) were resolved through discussion between KR
and JvD [25].
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Results
Participants
In total, 20 potential participants were approached, of
whom two declined to participate; one due to time con-
straints and one considered him/herself not suitable for
this study. Eventually, seventeen interviews were conducted
face-to-face and one participant answered the questions by
email. Interviews (excluding email contact) lasted on
average 49 min [range:31–72 min]. Twelve participants
were male (66.7%). Participants had a mean age of
49.7 years (SD = 8.4). Sixteen participants were healthcare
decision-makers working at the macro- (n = 5; labelled as
MA1-5), meso- (n = 4; labelled as ME1-4), or micro-level
(n = 7; labelled as MI1-7), and two were health economists
(labelled as HE1-2). Macro-level decision-makers worked
at the Dutch National Healthcare Institute (n = 4) or the
Dutch Ministry of Health, Welfare and Sports (n = 1).
Meso-level decision-makers worked for a health insurance
company (n = 2) or as a guideline development consultant
(n = 2). All micro-level decision-makers were physicians
(n = 7). Participants had various educational backgrounds,
but mostly medical (55.6%) and economic (27.8%) (Table 1).
Results of the structured interview questions
Knowledge of economic evaluations
While 63% of the participants working at the macro- and
meso-level (excluding health economists) indicated that
they had received some training in economic evaluation-
related topics, none of those working at the micro-level
had received such training.
When asked about what they associated with the term
‘economic evaluation’, participants frequently thought it
to be solely a calculation of costs and many were not aware
of the existence of various kinds of economic evaluations.
“I think that this would provide a proper overview of all
costs. (…) Possibly, also compare those costs with one
another, but in my opinion an economic evaluation does
not amount to much more than that. I wouldn't actually
correlate it with effectiveness.” (ME4) Of the participants,
36% were able to give a correct definition of the concept of
CEA. Other participants thought it to solely include costs
or thought its outcome depended on a predetermined goal,
as illustrated by the following quote; “Cost-effectiveness of
course really depends on the stated goal: when is a treat-
ment effective? What is the objective you are aiming for?”
(MI5) Although 36% of participants were able to give a cor-
rect definition of the concept of CUA, many had never
heard of the term, or thought it to be related to ‘utilization’.
One participant, for example, responded; “It seems to me
more a technical term, frankly. (…) Utilization no, I don’t
have an immediate explanation.” (MI5). Most participants
indicated familiarity with the concept of CBA, but only half
was able to give a correct definition. Some participants
thought it to be a broader concept compared to CEA, i.e.
more costs and effects are taken into account. As one par-
ticipant stated: “And with CBA you weigh all the effects of
the intervention. So also the effects on production loss. Well,
all social effects, I think?" (MI4).
Results of the semi-structured interview questions
The (sub-) themes that emerged during the analysis of
the current and potential use of economic evaluations
for healthcare decision-making, as well as the experi-
enced barriers and facilitators to the use of such studies
will be discussed below, and will be illustrated by quotes.
Current use of economic evaluations
Participants generally agreed that there is a need for
improving the efficiency of healthcare. The use of eco-
nomic evaluations was therefore thought to be inevitable.
One participant, for example, stated; “I believe that a 30%
cost increase took place there [in Mental Healthcare] in
just a few short years (…) Well, in that case it's definitely
worthwhile to pay attention to economic evaluations. If we
allow costs to keep on rising, we will soon have no schools
left and no asphalt on our roads.” (MA1) Nonetheless, the
current use and impact of economic evaluations in health-
care decision-making seemed to be limited. Participants
generally indicated that economic evaluations were not a
dominant factor in the decision-making process and that
economic evaluations hardly ever impacted the inclusion
or exclusion of a specific treatment in the basic health
insurance package. One participant, for example, stated;
“Up until now, I have had to conclude that economic
evaluations do not form the deciding factor, or hardly
ever, in reaching a negative package advice. We always
examine cost-effectiveness, but when matters come to a
head, you realise that neither the government nor society
Table 1 Baseline characteristics of the study population
Baseline characteristics Total n = 18
Male [n (%)] 12 (66.7)
Age (years) [mean (SD)] 49.7 (8.4)
Educational training [n (%)]
Medical 10 (55.6)
Economic 5 (27.8)
Medical + economic 1 (5.6)
Remaining 2 (11.1)




Health economists 2 (11.1)
Note: Macro-level: decision-makers working at the national level; Meso-level:
decision-makers working at the regional or local level; Micro-level: decision-makers
working in the individual patient setting
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is ready to make negative reimbursement decisions on
cost-effectiveness results.” (MA2).
Participants indicated that reimbursement and/or treat-
ment decisions are typically based on the effectiveness of a
treatment, rather than on its cost-effectiveness, as well as
physicians’ desire to provide a certain treatment to their
patients. Some participants attributed the limited use of
economic evaluations to the fact that their necessity is not
sufficiently recognized, both by healthcare decision-makers
and the general population. As one health economist meta-
phorically stated; “One way or another, it's as if the water
has to rise even higher before we decide that we need to
build dikes." (HE1).
Even though the role of economic evaluations in health-
care decision-making was considered limited, some partic-
ipants were able to provide examples of decision-making
processes in which economic evaluations have been con-
sulted. At the macro-level, for example, economic evalua-
tions were used in the process of determining the content
of the basic health insurance package, during price negoti-
ations between the Dutch Ministry of Health, Welfare,
and Sports and pharmaceutical companies, and during the
implementation of a population wide screening tool. At
the meso-level, economic evaluations have been used dur-
ing the development of clinical guidelines and the imple-
mentation of innovations within healthcare organizations.
Within healthcare organizations, however, only CBAs
were used. Participants were not able to provide examples
of the use of economic evaluations at the micro-level.
Potential use of economic evaluations
Participants provided various examples of decision-making
processes during which the use of economic evaluations
could prove to be beneficial. At the macro-level, the
government could use economic evaluations to deter-
mine what expenditures, within the healthcare sector
or even in other sectors, are likely to provide the best
value for money. Furthermore, economic evaluations
could be used during price negotiations between health
insurers and healthcare providers (meso-level) as a
means to generate the lowest healthcare prices possible.
Other options for using economic evaluations at the
macro-level include the narrowing of medical indica-
tions (e.g. defining patient groups for whom specific
treatments are cost-effective and for whom they are
not) and improvements in the organization of healthcare
processes (e.g. decisions to shift certain treatments from
secondary to primary care, and vice versa). Even though
participants saw several opportunities for extending the use
of economic evaluations at the macro- and meso-level, al-
most all agreed that there was no room for using economic
evaluations in the individual patient setting (micro-level).
One of their main arguments was that talking about costs
would potentially disrupt the doctor-patient relationship.
This is illustrated by the following quote; “Patients become
very suspicious when you start talking about costs. (…) In
fact, it can stand in the way of a doctor-patient relation-
ship.” (MI4). Some participants also emphasized that im-
proving the efficiency of healthcare ought not to be the
responsibility of the individual healthcare provider. As one
health economist noted; “In my opinion, the preconditions
under which physicians work, that is, the financial frame-
work that we succeed in creating with one another, are not
the responsibility of individual doctors.” (HE1).
Barriers to the use of economic evaluations
Participants identified various factors that currently pre-
vent economic evaluations from being extensively used
in healthcare decision-making.
Lack of resources: All participants indicated that a lack
of resources (i.e. time, money, skills) often prevent
economic evaluations from being used in healthcare
decision-making. As indicated by one participant: “But
the only thing the profession says is, bring on the money.
(…) Money really is the only thing.” (ME4).
Methodological factors: Participants identified various
kinds of barriers related to the methodology of eco-
nomic evaluations. An important barrier was the way in
which costs are typically valued in economic evaluations.
Some participants pointed out that, while costs are often
based on standard prices in economic evaluations, they
may vary extensively in reality due to factors such as the
jurisdiction in which a decision is made as well as the
size and degree of specialisation of a healthcare facility.
As one participant noted; “But costs differ enormously
across countries, due to differences in the cost of equipment,
personnel etc. So it has to be determined per country separ-
ately. (…) Even within the Netherlands, the price of a day
spent in a hospital differs across hospitals.” (MI5) Many
prices in the Dutch healthcare sector are set during nego-
tiations between health insurers and healthcare providers,
and can therefore differ enormously from standard prices.
Likewise, economic evaluations are often conducted with
only a couple of perspectives, such as the societal one that
considers all costs and consequences including those
outside of the healthcare sector. Consequently, many
economic evaluations are not directly applicable to spe-
cific decision-making contexts. As one participant noted;
“An example of a concrete matter that we are struggling
with is whether you should only include direct costs or also
indirect costs. (…) We calculated that, in a given scenario,
there will be a certain number of prescriptions and that
this will lead to a certain reduction in complications and
mortalities. If we would also include the prevention of
mortalities, however, the cost-saving of €18 million
would change in a cost-increase of about €240 million…”
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(ME3). Another barrier is that healthcare decision-makers
often poorly understand outcome measures used in eco-
nomic evaluations. Participants had difficulties with inter-
preting QALYs, viewed them of limited value to long-term
care, and were uncertain about their transferability across
countries. As for their limited value to long-term care, one
health economist stated “The trade-off between curative
and long-term care is always a theme, as you won’t get far
using QALYs. Then you need something else and can you
still weigh those results then?” (HE2) Some participants
were also concerned about the existence of interventions
of which the results are difficult to measure. As indicated
by one participant: “In paediatrics, it is the professions
whose effectiveness is not so obvious that we need most,
such as psychologists, physiotherapists; the paramedics in
fact. But I think it will be no easy task to demonstrate their
cost-effectiveness.” (ME3).
Lack of confidence in economic evaluations: In the case
of model-based economic evaluations, participants doubted
their reliability due to the complexity of the healthcare
system, which they considered to be hard to account for in
a model. As one participant noted; “A model is a simplifica-
tion of reality. (…) I think that is where the problem in
healthcare begins. There are so many influencing factors
(…) making it very difficult to construct such a model.”
(MA1). Also, some participants indicated to lack confidence
in economic evaluations in general. They attributed this to
the fact that economic evaluations are sometimes funded
or performed by the supplier of the treatment under study
(i.e. there can be an inherent conflict of interest). This is
illustrated by the following comment: “I think there is also
research showing that if a supplier initiates it [the study],
the results often turn out more positive.” (MI3).
Lack of a formal willingness-to-pay threshold: Partici-
pants indicated that the lack of a formal willingness-to-pay
threshold is an important barrier to the use of economic
evaluations in healthcare decision-making. Therefore, most
participants were in favour of establishing such threshold.
As one participant noted; “I find it inconsistent that we
aren’t brave enough to talk about what we want to spend
on the life of a human being in the Netherlands. What is a
life-year gained allowed to cost?” (MI6) Aside from the fact
that the establishment of a formal willingness-to-pay
threshold may help decision-makers in choosing between
alternatives, it may also release physicians of the responsi-
bility of incorporating efficiency considerations into the
individual patient setting. This reasoning is substantiated
by the following comment; “I can quite understand that
physicians say it is going too far to expect them to deter-
mine the limits (…) If you ask me, it is entirely reason-
able that physicians need some help with this.” (MA1)
Although a formal willingness-to-pay threshold may
improve the uptake of economic evaluations, participants
generally agreed that it would be difficult to set such a
threshold. Participants emphasized that when determining
the maximum cost per additional unit of effect, many fac-
tors should be taken into account, including the prevalence
and severity of a disease, the patients’ age, preferences, and
prognosis, and the availability of alternative options. As one
participant noted “It matters a lot whether alternative treat-
ment options are available. (…) If not, healthcare decisions
concern questions about life and death” (MA2). According
to some participants, it is therefore unethical to use a fixed
willingness-to-pay threshold, particularly when it concerns
life-threatening diseases. As such, it was suggested by some
participants that a willingness-to-pay threshold should be
extendible or categorized. The few participants who dis-
agreed with the need for a formal willingness-to-pay thresh-
old did so because they thought that savings could still be
made in other areas (e.g. by reducing the number of
unnecessary diagnostic tests) or because they felt that
they would lose some of their authority as physicians.
Another participant feared that the introduction of a
formal willingness-to-pay threshold would lead to fu-
ture economic evaluations producing incremental cost-
effectiveness ratios below the threshold, particularly in
the case of modelling studies; “I think models are easily
influenced. And if you're going to choose a fixed thresh-
old then you will see that the results of all models go
toward that threshold.” (ME3).Lack of relevant eco-
nomic evaluations: Participants indicated a need for
economic evaluations that are directly applicable to
their decision-making context, whereas economic evalua-
tions are often based on restrictive patient populations
and/or settings, and are sometimes already outdated at
the time of publication. As one participant indicated; “An
awful lot of economic evaluations are based on selective
groups of patients (…) Generally, trial patients are not the
same as those you encounter in daily practice” (MI1).
Public resistance: Participants indicated that for eco-
nomic evaluations to be used in healthcare decision-
making, it is essential that not only decision-makers, but
also members of the general population understand, ap-
preciate, and support their use. This is due to the
Dutch healthcare system being largely publicly funded.
Decisions made within this system therefore involve
essentially the entire population, because everyone con-
tributes to the financing of healthcare. Several partici-
pants, however, thought the general population is ‘not
yet ready’ to accept efficiency considerations as a factor
in healthcare decision-making. They attributed this to
the fact that most people either misunderstand the pur-
pose of economic evaluations or consider the idea of a
maximum price for healthcare unacceptable, particu-
larly when they are the ones being sick. One participant
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explained this as follows; “When you have a problem,
you want the best possible care. At such a moment, you
are not interested in the macro-economic aspect that it
will lead to enormous costs if it happens a thousand
times.” (MI2) Some participants also believed the gen-
eral population’s knowledge of economic evaluations to
be insufficient. As one participant noted; “Total costs
and cost-effectiveness are all jumbled up together and
we have discovered …. [in a research project] that even
the most well-educated people really do not know how it
works.” (MA2) Participants therefore believed that the
general population needs to have some basic knowledge
of (the purpose of) economic evaluations in order for
them to be able to substantiate their acceptance or rejec-
tion of the use of economic evaluations. As indicated by
one participant: “The price of a drug is something patients
can comprehend, whereas concepts such as QALYs are not.
While, on the other hand, I think it is a good tool [eco-
nomic evaluations], because people might think ‘my life
has no price, I should get the best possible care’, but cost-
effectiveness results are more nuanced in that the costs are
weighed against the effectiveness of a drug” (MA3).
Ambiguity among decision-makers about the physicians’
responsibility for improving the efficiency of healthcare:
Participants indicated that in order for economic evalua-
tions to be used in healthcare decision-making, decision-
makers themselves need to feel more responsibility for
improving the efficiency of healthcare. However, since the
main role of physicians is to act in a patient’s best interest,
it is not self-evident that they can embrace such a respon-
sibility. This is underscored by the following statement of
a participating physician: “I definitely want to keep it out
of surgery. Because I find it very difficult if at a certain
stage I have to make choices based on financial criteria
only.” (MI3) While participants working at the macro- and
meso-level generally agreed that physicians should con-
tribute to improving the efficiency of healthcare, physi-
cians themselves did not agree on what this should entail.
Some of them noted that the use of economic evaluations
in the individual patient setting may raise ethical con-
cerns, as it can appear to be in contradiction with the
Hippocratic Oath. As one participant noted; “Well, I think
(…) naturally, we want to give patients what we think they
need and this represents a big barrier if a cost-effectiveness
analysis shows that it is actually too expensive, while we
feel that the patient does have a right to it. (…) this is at
odds with our oath.” (MI4) The Hippocratic Oath reminds
physicians of their social responsibility as well as their
responsibility for the individual patient; i.e. two tasks that
are often incompatible when costs are considered. This is
illustrated by the fact that one participating physician
stated; “Up until a few years ago, the crux of the matter
was in fact that you always gave people the care they
needed and no-one even considered the cost. I think that,
as physicians, we find this inversion extremely difficult,
really I do.” (MI7), whereas a decision-maker working at
the meso-level argued; “This is actually mentioned in the
Hippocratic Oath (….) cost-effectiveness is a part of the
oath that we all take. This is something that physicians
sometimes forget (….)” (ME1).
Incentives to treat: Some participants regarded the abun-
dance of ‘incentives to treat’ in the healthcare system as a
barrier to the use of economic evaluations. As the Dutch
healthcare system currently has a fee-for-service system,
physicians and/or the organizations they work for, make
money by treating patients, whereas abstention from
treatment generates less income. Moreover, patients often
prefer some treatment than no treatment. As a conse-
quence, if physicians feel responsibility for improving the
efficiency of healthcare, it is still difficult for them to act
accordingly. As one participant noted; “The human body
is an inexhaustible source of income. As long as these
stimuli exist, the problem will never be solved. There are
simply financial stimuli for taking action, for doing
something. The system does not have stimuli for making
economic use of your resources” (MI1).
Limited ability to shift resources across sectors: Another
barrier to the use of economic evaluations concerns the
decision-makers’ limited ability to shift resources between
and within sectors. To illustrate, if an economic evaluation
shows that a specific treatment is more likely to be cost-
effective if provided in primary care than in secondary care,
it would be necessary to shift resources within the health-
care sector, but this is not easily executed. If an economic
evaluation is performed from the societal perspective,
savings flowing into non-healthcare sectors can lead to
positive cost-effectiveness results, whereas the cost-
effectiveness results for the healthcare sector itself may be
unfavourable. The latter is illustrated by the following com-
ment; “How do you process, for instance, benefits that are
accrued outside healthcare? (…) Because then the outcome
of an analysis would be that everything [within the health-
care sector] would become much more expensive and that
could hamper implementation, while it does actually lead
to results, just not in healthcare.” (ME3).
Facilitators for the use of economic evaluations
The most frequently mentioned facilitator for extending
the use of economic evaluations was educating decision-
makers about how to understand and interpret economic
evaluations of health technologies and how to use them in
resource allocation decision-making. Participants empha-
sized that some basic training about health economics,
and economic evaluations in particular, should be included
in the medical curriculum. One participant, for example,
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stated; “This is an aspect of training that is completely
neglected, even in medical follow-up training.” (MI1)
According to the participants, health economists could
do their bit by presenting their results in a clearer and
more understandable way. This is exemplified by the
following comment; “Well, I think that perhaps the lan-
guage used by health economists should be more neutral,
with more layman's terms, so that it is at least clearer; they
should use plainer language, especially for those who are
less well educated.” (MA3) Participants also recognized
the necessity of educating the general population about
(the purpose of) economic evaluations in order to build
the necessary public acceptance. As one participant noted;
“It is often very difficult to get such abstract ideas about
cost-effectiveness across and it actually demands a lot of
insight.” (MA2) Moreover, financial and intellectual sup-
port was emphasized as a requirement for making the use
of economic evaluations feasible and to create incentives
for decision-makers to start using them. As one par-
ticipant noted; “You need support for cost-effectiveness
analysis, because it is not so easy” (MI4) Some partici-
pants were also of the opinion that the reliability,
consistency, and transparency of economic evaluations
themselves ought to be improved and that industry-
funded studies should be assessed more critically. As
one participant stated; “I am actually in favour of spending
more money on carrying out, or improving, economic
evaluations, because this would result in less bias. Be-
cause currently many of them are carried out by private
manufacturers, so from that point of view, you would
like a more trustworthy assessment” (MA3).
Discussion
Main findings
This study illustrates a need to advance Dutch health-
care decision-makers’ economic evaluation skill set, as
their current knowledge of economic evaluations is quite
modest. Moreover, even though participants were able
to provide some examples of Dutch healthcare decisions
in which economic evaluations were consulted, the
current use and impact of such studies appeared to be
limited at best. Nonetheless, decision-makers recognized
the importance of economic evaluations and saw several
opportunities for extending their use at the macro- and
meso-level, but not at the micro-level. This disparity be-
tween the limited use of economic evaluations and the
decision-makers’ recognition of their importance might
be explained by the many barriers decision-makers expe-
rienced with their use (e.g. lack of required resources,
lack of formal willingness-to-pay threshold).
Comparison with the literature
The present findings are in line with those of previous
studies demonstrating that the use and impact of
economic evaluations of health technologies in health-
care decision-making is limited in most Western coun-
tries [12–17]. Also, in most of the previous studies
comparable barriers and facilitators to the use of eco-
nomic evaluations were identified [12]. The Dutch study
that explored the use of economic evaluations in health-
care decision-making prior to the Dutch healthcare re-
form also found decision-makers to have a positive
attitude towards economic evaluations, whereas their ac-
tual use and knowledge of such studies was limited [17].
The decision-makers participating in that study also indi-
cated difficulties with moving resources across sectors, a
lack of relevant studies, a lack of confidence in model-
based and industry-sponsored economic evaluations, and
a lack of economic evaluation knowledge to obstruct to
the use of such studies in daily decision-making practice,
whereas other barriers identified in the present study (e.g.
lack of a formal willingness-to-pay threshold, public resist-
ance) were not mentioned. In both studies, macro-, meso-
, as well as micro-level decision-makers were included and
semi-structured interviews were used for answering the
research questions. All in all, this indicates that the use of
economic evaluations has not increased extensively over
the last decade, whereas there seem to have been some
developments since then, with the most important one
being the fact that the majority of the participants in the
present study argued in favour of the establishment of a
formal willingness-to-pay threshold, whereas participants
in the previous study were generally against the introduc-
tion of such a threshold [17].
Strengths and limitations
A strength of the present study is that it is qualitative.
An important advantage of a qualitative design is that it
allows for the questions being studied to be explored in
greater detail and for the collection of in-depth informa-
tion on participants’ views and opinions. The latter is
particularly important because many of the previous
studies in this area, and those conducted outside the
Netherlands in particular, relied heavily on survey methods,
which limited the participants’ freedom of response [12].
As such, the present findings are likely to be relevant to
other jurisdictions as well, as many other countries are also
trying to deal with high and rising healthcare costs by
searching for means to maximize health effects within their
fixed healthcare budget. Another strength concerns the
fact that this was the first study since the Dutch healthcare
reform in 2006 to explore the current and potential use
of economic evaluations in healthcare decision-making.
Given that the reform was inter alia aimed at improving
the efficiency of healthcare, our study serves a critical
role in assessing whether the reform influenced whether
economic evaluations are used to a greater extent than in
the past to address the issue of efficiency.
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A first limitation of the present study concerns the fact
that, even though conscious efforts were made to include
healthcare decision-makers working at the macro-,
meso-, and micro-level, it is uncertain if representatives
from all stakeholders were included in the study. Another
limitation is the risk of selection bias, as some partici-
pants were selected with the help of the Dutch National
Healthcare Institute. This may have resulted in partici-
pants having a greater interest in the topic of this study
than the average healthcare decision-maker, resulting in
an overestimation of the actual use and knowledge of
economic evaluations in the healthcare sector.
Recommendations for research and practice
The use of economic evaluations in healthcare decision-
making has the potential to improve the efficient use of
resources, though this study suggests that the current
use and impact of such studies is generally limited in the
Dutch healthcare system. Therefore, strategies are needed
to overcome the barriers that currently prevent economic
evaluations from being used more extensively. Some pre-
liminary recommendations as to how to overcome these
barriers will be discussed below [26]. These recommenda-
tions are based on the present findings as well as relevant
literature, but further research is needed to establish what
recommendations will eventually be most effective in
improving the uptake of economic evaluation in daily
decision-making practice.
In order for economic evaluations to reach relevant
decision-makers, it is essential to publish such studies in
(non-scientific) journals and/or on websites that are easily
accessible (e.g. open access journals). To provide health-
care decision-makers with relevant and ‘ready-to-use’ in-
formation, there may be value in developing a national
database in which all relevant economic evaluations are
collected and complemented by critical, easy-to-read sum-
maries (e.g. a database comparable to the UK NHS-EED
database) [27]. The addition of critical summaries is essen-
tial, as decision-makers often lack the time and skill set
required to critically appraise economic evaluations [28].
Another possible means to improve the decision-makers’
economic evaluation skill set might be educating them
about economic evaluation methods. Healthcare decision-
makers may be educated through a variety of avenues,
including the development of (online) handbooks and
workshops, integrating economic evaluation methods into
the medical curriculum, and by involving them in the
commissioning and/or execution of studies [15, 25, 29].
To improve the perceived credibility of economic evalua-
tions, guidelines are needed on how to conduct, report,
and critically appraise such studies. Though several guide-
lines for the conduct and reporting of economic evalua-
tions are already available (e.g. [9, 30, 31]), these could be
supplemented with more user friendly guidelines designed
specifically for practitioners. Another possible means to
improve the use of economic evaluations is to establish a
formal willingness-to-pay threshold for QALYs. Partici-
pants in this study were generally in favour of the intro-
duction of such a threshold, but they rejected the idea of
an explicit cut-off point. Instead, they were in favour of a
bandwidth or categorization. Few of them, however, were
willing to make a statement about the possible level of the
threshold.
Participants also indicated a need for economic evalua-
tions that are directly applicable to their decision-making
context. Therefore, additional economic evaluations that
are timely and relevant for healthcare decision-makers
need to be performed. The fact that economic evaluations
performed from the societal perspective are not directly
applicable to a specific decision-making context may be
overcome by using the two-perspective approach advo-
cated by Brouwer et al. [32]. When using such an ap-
proach, economic evaluations are conducted from both
the healthcare system and the societal perspective. In
this way, economic evaluations are directly applicable
to the healthcare sector, while simultaneously providing
an indication of whether the “local perspective” of the
healthcare sector is consistent with social optimality
(i.e. societal welfare maximization) [32].
Incentives are needed for healthcare providers to provide
care that is most likely to be cost-effective. One way to deal
with the incentives to “over treat” may be to move away
from a predominant “fee-for-service” system to a “pay-for-
performance” system, in which healthcare providers receive
a bonus if they meet or exceed certain agreed-upon quality
or performance measures [33, 34].
Ethical considerations, such as the physicians’ respon-
sibility to act in their patients’ best interest, may partially
be dealt with by raising the physicians’ awareness of the
fact that the provision of all possible treatment options,
irrespective of their (cost-) effectiveness, might reduce
the accessibility and quality of care to other clients and
to Dutch society in general [35]. However, it is unrealis-
tic to expect healthcare providers to make such deci-
sions on their own [36, 37]. Therefore, identifications of
cost-effective treatment options are best undertaken at
the macro- and meso-level. This could take the form of
narrowing medical indications and concurrently the defin-
ition of the basic healthcare package (at a macro-level), as
well as developing clinical, best practice guidelines (at a
meso-level).
Finally, strategies should be developed to overcome the
public resistance to the use of economic evaluations in
healthcare decision-making. Such strategies may include
national campaigns (e.g. educating people about the im-
portance of improving the efficiency of healthcare through
the use of economic evaluations) as well as an increased
transparency about the actual cost of treatment.
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Conclusion
Even though the use of economic evaluations in healthcare
decision-making can potentially help decision-makers in
allocating scarce resources as efficiently as possible, this
study demonstrated that the current use and impact of
economic evaluations in Dutch healthcare decision-making
is limited at best. Therefore, strategies are needed to over-
come the barriers that currently prevent economic evalua-
tions from being used extensively.
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